Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.


On October 21, 1993, Drs. Mitchell Creinin and Phillip Darney of the University of California at San Francisco publicized the results of their study of methotrexate as an abortifacient. The study, published in the journal Contraception, involved ten women, eight of whose pregnancies were successfully terminated. (Since the original study, more than fifty women have undergone the experimental procedure.)

The most significant aspect of the UCSF study, according to Nancy Tompkins, editor of the pro-choice newsletter Choosing Choice, is the fact that methotrexate is already on the market and FDA-approved for other purposes. Before its use as an abortifacient can be anything other than experimental, however, someone has to apply for a “supplemental indication” approval, which is generally easier to get than a new-drug approval.

Others are less optimistic than Tompkins. Thus far, no drug company has publicly requested a supplemental indication approval, and according to Wayne Koberstein, editor of Pharmaceutical Executive, “it is very unlikely that any large brand-name company will take this on.” Ironically, what may prevent methotrexate from becoming widely available for abortion is its low cost (four dollars per dose compared to two hundred dollars for RU 486). Because of this, methotrexate is unlikely to be a big profit-maker, and companies may be unwilling to risk the wrath of antiabortion groups by marketing it. Even if a company does take this chance, the drug’s approval is probably at least one or two years away.

IT'S NOT THAT WE'RE SCREWED WITHOUT TRUMP:

"It's that we're screwed with or without him if we can't show the public that what we do matters for the long term," writes Mother Jones CEO Monika Bauerlein as she kicks off our drive to raise $350,000 in donations from readers by July 17.

This is a big one for us. It's our first time asking for an outpouring of support since screams of FAKE NEWS and so much of what Trump stood for made everything we do so visceral. Like most newsrooms, we face incredibly hard budget realities, and it's unnerving needing to raise big money when traffic is down.

So, as we ask you to consider supporting our team's journalism, we thought we'd slow down and check in about where Mother Jones is and where we're going after the chaotic last several years. This comparatively slow moment is also an urgent one for Mother Jones: You can read more in "Slow News Is Good News," and if you're able to, please support our team's hard-hitting journalism and help us reach our big $350,000 goal with a donation today.

payment methods

IT'S NOT THAT WE'RE SCREWED WITHOUT TRUMP:

"It's that we're screwed with or without him if we can't show the public that what we do matters for the long term," writes Mother Jones CEO Monika Bauerlein as she kicks off our drive to raise $350,000 in donations from readers by July 17.

This is a big one for us. So, as we ask you to consider supporting our team's journalism, we thought we'd slow down and check in about where Mother Jones is and where we're going after the chaotic last several years. This comparatively slow moment is also an urgent one for Mother Jones: You can read more in "Slow News Is Good News," and if you're able to, please support our team's hard-hitting journalism and help us reach our big $350,000 goal with a donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate